Log In
BCIQ
Print this Print this
 

etirinotecan pegol (Onzeald) (NKTR-102)

  Manage Alerts
Collapse Summary General Information
Company Nektar Therapeutics
DescriptionTopoisomerase I (TOP1) inhibitor-polymer conjugate
Molecular Target Topoisomerase I (TOP1)
Mechanism of ActionTopoisomerase I inhibitor
Therapeutic ModalityMacromolecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$80.0M

$20.0M

$60.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/01/2016

$80.0M

$20.0M

$60.0M

Get a free BioCentury trial today